The world is not enough - the value of increasing registry data in idiopathic pulmonary fibrosis

被引：3
作者：
Moor, C. C. [1 ]
Kreuter, M. [2 ,3 ]
Luppi, F. [4 ]
Wuyts, W. A. [5 ]
机构：
[1] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands
[2] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis Pneumol & Resp C, Thoraxklin, Heidelberg, Germany
[3] German Ctr Lung Res, Heidelberg, Germany
[4] Univ Milano Bicocca, Resp Unit, S Gerardo Hosp, Monza, Italy
[5] Univ Hosp Leuven, Dept Resp Med, Leuven, Belgium
来源：
RESPIRATORY RESEARCH | 2020年 / 21卷 / 01期
关键词：
PIRFENIDONE; NINTEDANIB; DIAGNOSIS; CAPACITY; OUTCOMES; SAFETY;
D O I：
10.1186/s12931-020-01377-1
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Management of Idiopathic Pulmonary Fibrosis
    Pleasants, Roy
    Tighe, Robert M.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (12) : 1238 - 1248
  • [22] Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)
    Bouros, Demosthenes
    Daniil, Zoe
    Papakosta, Despoina
    Antoniou, Katerina M.
    Markopoulou, Katerina
    Kolilekas, Likurgos
    Konstantopoulos, George
    Papiris, Spyros
    RESPIRATION, 2018, 96 (01) : 41 - 47
  • [23] Idiopathic pulmonary fibrosis: An update
    Spagnolo, Paolo
    Sverzellati, Nicola
    Rossi, Giulio
    Cavazza, Alberto
    Tzouvelekis, Argyris
    Crestani, Bruno
    Vancheri, Carlo
    ANNALS OF MEDICINE, 2015, 47 (01) : 15 - 27
  • [24] Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
    Tzouvelekis, Argyrios
    Karampitsakos, Theodoros
    Ntolios, Paschalis
    Tzilas, Vasilios
    Bouros, Evangelos
    Markozannes, Evangelos
    Malliou, Ioanna
    Anagnostopoulos, Aris
    Granitsas, Andreas
    Steiropoulos, Paschalis
    Dimakou, Katerina
    Chrysikos, Serafeim
    Koulouris, Nikolaos
    Bouros, Demosthenes
    FRONTIERS IN MEDICINE, 2017, 4 : 1 - 1
  • [25] A global registry for idiopathic pulmonary fibrosis: the time is now
    Ryerson, Christopher J.
    Corte, Tamera J.
    Collard, Harold R.
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (02) : 273 - 276
  • [26] Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists
    Fidler, Lee M.
    Burns, Karen E. A.
    Singer, Lianne
    Kiss, Alex
    Shapera, Shane
    Stanbrook, Matthew B.
    CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE, 2020, 4 (03) : 165 - 173
  • [27] The safety of new drug treatments for idiopathic pulmonary fibrosis
    Fletcher, Sophie
    Jones, Mark G.
    Spinks, Katherine
    Sgalla, Giacomo
    Marshall, Ben G.
    Limbrey, Rachel
    Richeldi, Luca
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (11) : 1483 - 1489
  • [28] Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry
    Fahim, Ahmed
    Loughenbury, Maria
    Stewart, Iain
    Agnew, Sarah
    Almond, Howard
    Casimo, Leo
    Chaudhuri, Nazia
    Fletcher, Sophie, V
    Haney, Sarah
    Ho, Ling-Pei
    Hodkinson, Clare
    Minnis, Paul
    Palmer, Evelyn
    Wilson, Andrew M.
    British Thorac Soc
    BMJ OPEN RESPIRATORY RESEARCH, 2025, 12 (01)
  • [29] Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis
    Behr, Juergen
    Bonella, Francesco
    Frye, Bjoern C.
    Guenther, Andreas
    Hagmeyer, Lars
    Henes, Joerg
    Klemm, Philipp
    Koschel, Dirk
    Kreuter, Michael
    Leuschner, Gabriela
    Nowak, Dennis
    Prasse, Antje
    Quadder, Bernd
    Sitter, Helmut
    Costabel, Ulrich
    PNEUMOLOGIE, 2023, 77 (02): : 94 - 119
  • [30] Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis
    King, Christopher S.
    Nathan, Steven D.
    CURRENT OPINION IN PULMONARY MEDICINE, 2015, 21 (05) : 479 - 489
12345